Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

61
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
61
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

358
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

263
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

59
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
59
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

926
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
926

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic dysfunction-associated steatotic liver disease in the cardio-renal-metabolic syndrome: The silenced 'H'.

Medicina clinica·2026
Same author

MASLD as a reflection of fragmented care between primary care and specialist care: an expert opinion.

Revista espanola de enfermedades digestivas·2026
Same author

Expert-consensus recommendations and SEPD certification criteria for bariatric and metabolic endoscopy units. Position paper of the Sociedad Española de Patologia Digestiva (SEPD).

Revista espanola de enfermedades digestivas·2026
Same author

AI Integration in Spanish Undergraduate Medical Education: National Cross-Sectional Study.

JMIR medical education·2026
Same author

The histidine crossroad: An integrative theory of the gut-liver-vascular axis in MASLD.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort.

JHEP reports : innovation in hepatology·2026

Related Experiment Video

Updated: Apr 14, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

[Chronic hepatitis C: patients with mild disease].

Juan Carlos Quer1, Moisés Diago2, Javier Crespo3

  • 1Servicio de Aparato Digestivo, Hospital Universitario Joan XXIII, Tarragona, España.

Gastroenterologia Y Hepatologia
|April 25, 2015
PubMed
Summary

Chronic hepatitis C virus infection often presents with mild liver disease. Treatment advances, including direct-acting antivirals, are improving outcomes for hepatitis C patients.

Keywords:
BoceprevirChronic hepatitisHepatitis C virusHepatitis crónicaInterferonInterferónRibavirinRibavirinaTelaprevirVirus de la hepatitis C

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Experiment Videos

Last Updated: Apr 14, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

20.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Context:

  • Chronic hepatitis C virus (HCV) infection is typically asymptomatic with varying degrees of hepatic lesions.
  • Histopathologically, most patients present with mild liver disease at diagnosis.
  • Several factors influence fibrosis progression in mild cases, including age, infection duration, sex, HIV coinfection, transaminase levels, alcohol, metabolic factors, and steatosis.

Purpose:

  • To review current and emerging treatment strategies for chronic hepatitis C virus infection.
  • To discuss factors affecting fibrosis progression in patients with mild hepatitis C.
  • To highlight the evolving landscape of hepatitis C treatment with new antiviral agents.

Summary:

  • Standard treatment for genotype 1 HCV has been pegylated interferon and ribavirin, with improved response rates using first-generation protease inhibitors (boceprevir, telaprevir).
  • These protease inhibitors are effective and well-tolerated in patients with moderate fibrosis.
  • For non-genotype 1 HCV, pegylated interferon and ribavirin remain standard, but direct-acting antivirals like sofosbuvir and simeprevir are expected to alter treatment paradigms.
  • The introduction of new direct-acting antiviral agents promises to significantly change hepatitis C treatment strategies, though accessibility may be limited by cost and availability.

Impact:

  • Enhanced understanding of fibrosis progression factors in chronic hepatitis C.
  • Informed clinical decision-making regarding current dual therapies versus awaiting new direct-acting antivirals.
  • Potential for improved patient outcomes with the advent of novel, highly effective antiviral therapies for hepatitis C.